Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind, placebo-controlled Phase III study of NS-304 in intermittent claudication due to arteriosclerosis obliterans
jRCT2071250134Phase 3Recruiting
- Sponsor
- Nippon Shinyaku
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in intermittent claudication (IC) and arteriosclerosis obliterans comparing NS-304 arm with Placebo arm (2 arms). Primary endpoint: Change from baseline in natural log transformed peak walking time (ln PWT). Started Mar 2026; status: recruiting.
02
Drugs
selexipag
03
Conditions
intermittent claudication (IC)arteriosclerosis obliterans
Beyond the preview
Go deeper on jRCT2071250134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250134.